Cation-π and π-π stacking interactions allow selective inhibition of butyrylcholinesterase by modified quinine and cinchonidine alkaloids

Biochemical and Biophysical Research Communications

Volumn 404, Issue 4, 2011, Pages 935-940

  Nawaz, Sarfraz A ^a   Ayaz, Muhammad ^a   Brandt, Wolfgang ^a   Wessjohann, Ludger A ^a,b   Westermann, Bernhard ^a,b  

^a LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Acetylcholinesterase; Butyrylcholinesterase; Cinchonidine alkaloids; Inhibition kinetics; Molecular docking

Indexed keywords

CATION; CHOLINE; CHOLINESTERASE; CINCHONIDINE; NITROGEN; QUININE;

ARTICLE; BINDING COMPETITION; BINDING SITE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BINDING; ENZYME INHIBITION; KINETICS; MOLECULAR DOCKING; PREDICTION; PRIORITY JOURNAL;

BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; CINCHONA ALKALOIDS; HUMANS; QUININE;

EID: 79151477796     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.084     Document Type: Article

References (33)

1. Terry A.V., Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 2003, 306:821-827.
2. Darvesh S., Hopkins D.A., Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 2003, 2:131-138.
3. Tasker A., Perry E.K., Ballard C.G. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. Expert Rev. Neurother 2005, 5:101-106.
4. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
5. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 2003, 4:97-112.
6. Greig N.H., Utsuki T., Yu Q.-S., Zhu X., Holloway H.W., Perry T., Lee B., Ingram D.K., Lahiri D.K. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17:159-165.
7. Rivera-Becerril E., Joseph-Nathan P., Pérez-Álvarez V., Morales-Ríos M.S. Synthesis and biological evaluation of (-)- and (+)- debromoflustramine B and its analogues as selective butyrylcholinesterase inhibitors. J. Med. Chem. 2008, 51:5271-5284.
8. Yu S.Q., Holloway H.W., Utsuki T., Brossi A., Greig N.H. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J. Med. Chem. 1999, 42:1855-1861.
9. Ul-Haq Z., Khan W., Kalsoom S., Ansanti F.L. In silico modeling of the specific inibitory potential of thiophene-2, 3-dihydro-1, 5-benzothiazepine against BChE in the fomation of β-amyloid plaques associated with Alzheimer's disease. Theor. Biol. Med. Mod. 2010, 7:22-47.
10. Nicolet Y., Lockridge O., Masson P., Fontecilla-Camps J.C., Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 2003, 278:41141-41147.
11. Sussman J.L., Harel M., Frolow F., Oefiner C., Goldman A., Toker L., Silman I. Atomic structure of acetylcholnesterrase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 25:872-879.
12. Cokugras A.N. Butyrylcholinesterase: structure and physiological importance. Turk. J. Biochem. 2003, 28:54-61.
13. Colletier J.P., Fournier D., Greenblatt H.M., Stojan J., Sussman J.L., Zaccai G., Silman I., Weik M. Structural insights into substrate traffic and inhibition in acetylcholinesterase. EMBO J. 2006, 25:2746-2756.
14. Harel M., Schalk I., Ehret-Sabatier L., Bouet F., Goeldner M., Hirth C., Axelsen P.H., Silman I., Sussman J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Nat. Acad. Sci. U.S.A. 1993, 90:9031-9035.
15. Corey E.J., Xu F., Noe M.C. A rational approach to catalytic enantioselective enolate alkylation using a structurally rigidified and defined chiral quaternary ammonium salt under phase transfer conditions. J. Am. Chem. Soc. 1997, 119:12414-12415.
16. Berkessel A., Guixa M., Schmidt F., Neudoerfl J.M., Lex J. Highly enantioselective epoxidation of 2-methylnaphthoquinone (Vitamin K3) mediated by new cinchona alkaloid phase-transfer catalysts. Chem. Eur. J. 2007, 13:4483-4498.
17. Tozawa T., Nagao H., Yamane Y., Mukaiyama T. Enantioselective synthesis of 3, 4-dihydropyran-2-ones by domino Michael addition and lactonization with new asymmetric organocatalysts: cinchona-alkaloid-derived chiral quaternary ammonium phenoxides. Chem. Asian J. 2007, 2:123-134.
18. Li H., Wang Y., Tang L., Deng L. Highly enantioselective conjugate addition of malonate and â-ketoester to nitroalkenes: asymmetric C-C bond formation with new bifunctional organic catalysts based on cinchona alkaloids. J. Am. Chem. Soc. 2004, 126:9906-9907.
19. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharm. 1961, 7:88-95.
20. Choudhary M.I., Nawaz S.A., Zaheer-ul-Haq, Azim M.K., Ghayur M.N., Lodhi M.A., Jalil S., Khalid A., Ahmed A., Rode B.M., Atta-ur-Rahman, Ahmad V.U. Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer's disease therapy. Biochem. Biophys. Res. Commun. 2005, 332:1171-1177.
21. Nawaz S.A., Umbreen S., Kahlid A., Ansari F.L., Choudhary M.I. Structural insight into the inhibition of acetylcholinesterase by 2, 3, 4, 5-tetrahydro-1, 5-benzothiazepines. J. Enzyme Inhib. Med. Chem. 2008, 2:206-212.
22. Choudhary M.I., Nawaz S.A., Zaheer-ul-Haq, Lodhi M.A., Ghayur M.N., Jalil S., Riaz N., Yousuf S., Malik A., Gilani A.H., Atta-ur-Rahman Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem. Biophys. Res. Commun. 2005, 19:276-287.
23. Atta-ur-Rahman, Feroz F., Nawaz S.A., Khan M.R., Choudhary M.I. New Pregnan-type steroidal alkaloids from Sarcococca saligna and their cholinesterase inhibiting activity. Steroids 2004, 69:735-741.
24. Dixon M. The determination of enzyme inhibitors constant. Biochem. J. 1953, 5:170-171.
25. Segel I.H. Non-competitive inhibition (Simple intersecting linear non-competitive inhibition), in: enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems 1993, John Wiley and Sons, New York, pp 101-112.
26. Leatherbarrow R.J. GraFit Version 4.09 1999, Erithacus Software Ltd.
27. Raves M.L., Harel M., Pang Y.P., Silman I., Kozikowski A.P., Sussman J.L. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 1997, 4:57-63.
28. Molecular Operating Environment, Chemical Computing Group, 10 Operating System, Montreal, Canada, 2007.
29. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267:727-748.
30. Nissink J.W.M., Murray C., Hartshorn M., Verdonk M.L., Cole J.C., Taylor R. A new test set for validating predictions of protein-ligand interaction. Proteins Struct. Funct. Genet. 2002, 49:457-471.
31. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., Taylor R.D. Improved protein-ligand docking using GOLD. Proteins 2003, 52:609-623.
32. Korb O., Stützle T., Exner T.E. An ant colony optimization approach to flexible protein-ligand docking. Swarm Intell. 2007, 1:115-134.
33. Pymol: Available from: http://pymol.sourceforge.net/